La hipertrigliceridemia en la enfermedad coronaria ¿es un factor de riesgo?
DOI:
https://doi.org/10.31053/1853.0605.v73.n1.14285Palabras clave:
Hipertrigliceridemia, enfermedad coronaria.Resumen
La asociación entre hipertrigliceridemia y enfermedad arterial coronaria (EAC) es controvertida. Objetivo: establecer la relación entre el nivel de triglicéridos en pacientes con enfermedad coronaria, relacionar los valores elevados de triglicéridos con colesterol total, colesterol HDL, colesterol LDL, sobrepeso y obesidad en pacientes coronarios. Material Y Métodos: Se evaluaron retrospectivamente pacientes con y sin enfermedad coronaria demostrable que fueron asistidos en la consulta pública y privada en la Cátedra de Medicina I Unidad Académica de Medicina Interna Nº 3 del Hospital Córdoba y el Servicio de Cardiología de la Clínica Sucre de la ciudad de Córdoba, entre en 1 de enero y 31 de diciembre de 2009. Se consideró pacientes con enfermedad coronaria (casos) aquellos que tuvieron lesiones coronarias significativas las que mostraron una disminución de la luz arterial >50% `por medio de cinecoronariografía. (15)(16) y un grupo control sin enfermedad coronaria objetivable. . Se incluyeron pacientes entre 30 y 60 años de edad que tuvieran historia clínica completa. Resultados: El número total de pacientes incluidos fue de 100 casos, 64 casos en el grupo de pacientes coronarios y 36 en los no coronarios. 74% de sexo masculino, predominancia masculina en pacientes coronarios y femenina en no coronarios. 68% era mayor de 50 años. Los valores del lipidograma no mostraron diferencias estadísticamente significativas en pacientes no coronarios y coronarios Los valores promedio de TG fueron levemente más elevados en el grupo de no coronarios, aunque no mostraron diferencias estadísticamente significativas (p=0,7162). Conclusión: La hipertrigliceridemia no fue mayor en los pacientes coronarios y no se relacionó con el índice de masa corporal, en pacientes con sobrepeso y obesos.
Summary:
Hypercholesterolemia is a well known risk factor for coronary cardiovascular disease (CVD). However, the role of triglycerides in CVD risk remains controversial. Objective: to study triglyceride level and its relationship with Cholesterol, HDL and LDL Cholesterol level, obesity and overweight in patients with and without CVD. Material and Methods: we retrospectively studied patients with and without CVD who attended to Córdoba Hospital and Cardiology unit of Clínica Sucre at Córdoba city between 1° January to 31 st of December of 2009. We included patients with age between 30 to 60 years old with CVD and a control group. Results: 100 patients were included, 64 with CVD and 36 as a control group. 74% were male and 68% older than 50 years old. Lipid values were not statistically significant in both groups. Triglyceride level was higher in the control group, although the difference was not statistically significant (p=0, 7162). Conclusion: Triglyceride level was not higher in patients with CVD.Descargas
Citas
Conde CA, Factores de riesgo no tradicionales en la enfermedad coronaria, en: Esper RJ, Vilariño JO, Progresos en aterotrombosis, Desde la Genética Aplicada a la Medicina Personalizada, Cap 10, pp91-112, Ediciones Médicas del Sur, 2002.
Crespin SR, The Lipid Triad of the Insulin-Resistance Syndrome, How it contributes to Accelerated Atherosclerosis.PractDiabetol 1999, pp20-25.
Hokanson JE, Austin MA, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.J Cardiovasc Risk 1996; 3:213-229.
East C, Combined Hyperlipidemia as a Risk Factor for Premature Atherosclerotic Disease .Am J Med 1999; 107 (2A):46S-47S.
Jeppesen J, Hein HO, Suadicani P, ET AL, Triglyceride concentration and ischemic heart disease: an eight-year follow up in the Copenhagen Male Study. Circulation 1998; 97:1029-1036.
Hokanson JE, Austin MA, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213-229.
Haffner SM, Lehto S, Ronnemaa T, ET AL, Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-239.
Karpe F, Steiner G, Uffelman K, et al, Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1997; 106:83-97.
Villariño JO, CacharronJL.Esper RJ, et al, Evaluación de la función endotelial por eco-doppler. Influencia de la edad, sexo y factores de riesgo. RevArgCardiol 1998; 66(5):523-532.
Brunzell JD, Hokanson JE. Low-Density and High-Densily Lipoprotein Subspecies and Risk for Premature Coronary Artery Disease. Am J Med 1999; 107 (2A):16S-17S.
Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260:1917-1921.
Grundy SM, Balady GJ, Criqui MH, et al, Primary prevention of coronary heart disease: guidance from Framingham. A statement for health care professionals from the American Heart Association's Task Force on Risk Reduction, Circulation 1998; 97:1876-1887.
Haffner SM, Patients with Type 2 Diabetes: The Case for Primary Prevention. Am J Med 1999; 107 (2A):43S-45S.
Manninen V, Tenkanen L, Koskinen P, et al, Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85:37-45.
Levin DS, Gardiner GA JT, Coronariografía, en: Braunwald E (ED): Tratado de Cardiología (4ª ed).Interamericana, Mc Graw-Hill 1993, pp 293.
McHenry PL, O´Donnell J, Morris SN, et al, Abnormal exercise electrocardiogram in apparently healthy men: a predictor of angina pectoris as an initial coronary event during long-term follow up.Circulation 1984; 70:547.
Eknoyan G, AdolpheQuetelet (1796–1874)—the average man and indices of obesity.Nephrol Dial Transplant 2008; 23 (1): 47–51.
OMS, Organización Mundial de la Salud. euro.who.int. [En línea] [Citado el: 30 de noviembre de 2011.] http://www.euro.who.int/en/what-we-do/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi.
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM, Cleeman JI, Merz CN, et al, National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association. Circulation 2004; 110(2):227-39.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002; 106(25):3143-421.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.JAMA 2001; 285(19):2486-97.
Registro Nacional de Infarto Agudo de Miocardio de la Federación Argentina de Cardiología.RevFedArg 2004; 33:127–131.
Cullen P, Schulte H, Assmann G., The Münster Heart Sttudy (PROCAM), Total Mortality in Middle-Aged Men Is Increased at Low Total and LDL Cholesterol Concentrations in Smokers but Not in Nonmoskers.Circulation 1997;96:2128-2136.
Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A, No fasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women, JAMA 2007, 298(3):299-308.
Keys A, Coronary heart disease in seven countries, Circulation 1970; 41(suppl 1):1-211.
Gordon T, Castelli W, Higthdensuity lipoprotein as a protective factor against coronary disease: The Framingham study.Am J Med 1977; 62:698-706.
Esper RJ, Vilariño JO, Progresos en aterotrombosis, Desde la Genética Aplicada a la Medicina Personalizada, Ediciones Médicas del Sur, 2011.
Hopkins PN, et al, Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease.JACC 2005; 45:1003-12.
Coniglio RI, La hipertrigliceridemia como factor de riesgo para la aterosclerosis coronaria.ActBioquímClinLatinoam 1995; 29(2):129-37.
Kannel WB, Vasan RS, Triglycerides as vascular risk factors: new Epidemiologic Insights for Current Opinion in Cardiology.Curr Opin Cardiol 2009; 24(4):345–350.
Mora S, Rifai N, Buring JE, Ridker PM, Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events. Circulation 2008; 118:993–1001.
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A, Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women. JAMA 2007; 298:299–308.
Ridker PM, Rifai N, Cook NR, et al, Non-HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women.JAMA 2005; 294:326–333.
Jones JD, Chambliss L, Hipertrigliceridemia y enfermedad coronaria. Arch Fam Med 2000; 9:189-190.
Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298:309–316.
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299–308.
Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, et al, Triglyceride-mediated pathway. Lancet 2010; 376(9735):90.
Vakkilaien J, Steiner G, Ansquer JC, et al, Relationship between low-density lipoprotein praticle size, plasma lipoproteins an progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107: 1733-1737.
Keech A, et al, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus, The FIELD Study, randomized controlled trial, Lancet 2005;366:19849-1861.
Kim EH, Lee JB, Kim SH, Jo MW,et al. Serum Triglyceride Levels and Cardiovascular Disease Events in Koreans. Cardiology. 2015;131(4):228-35
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
La Revista de la Facultad de Ciencias Médicas de Córdoba (RFCM) adhiere a la política de Acceso Abierto y no cobra cargos a los autores para publicar, ni tampoco a lectores para acceder a los artículos publicados.
